Ahmad Khajeh-Mehrizi

Ahmad Khajeh-Mehrizi

Auto-generated profile, based on publicly available information

Ahmad Khajeh-Mehrizi

Department of Hematology-Oncology, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences (TUMS), Tehran, Iran

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2012 in Sleep and Breathing
Verified
Journal Article
Closed access
PDF file
KHKhosro Sadeghniiat Haghighi
Khosro Sadeghniiat Haghighi
Ali MontazeriAli Montazeri
Ali Montazeri
AMAhmad Khajeh Mehrizi
Ahmad Khajeh Mehrizi
OAOmid Aminian
Omid Aminian
AGAnia Rahimi Golkhandan
Ania Rahimi Golkhandan
MSMojtaba Sedaghat
Mojtaba Sedaghat

23 January 2015 in Quality of Life Research
Verified
Journal Article
Closed access
PDF file
KSKhosro Sadeghniiat-Haghighi
Khosro Sadeghniiat-Haghighi
Ali MontazeriAli Montazeri
Ali Montazeri
AKAhmad Khajeh-Mehrizi
Ahmad Khajeh-Mehrizi
MGMahsa Ghajarzadeh
Mahsa Ghajarzadeh
ZAZahra Banafsheh Alemohammad
Zahra Banafsheh Alemohammad
MSMojtaba Sedaghat
Mojtaba Sedaghat

3 August 2013 in Quality of Life Research
Verified
Journal Article
Closed access
PDF file
KSKhosro Sadeghniiat-Haghighi
Khosro Sadeghniiat-Haghighi
Ali MontazeriAli Montazeri
Ali Montazeri
AKAhmad Khajeh-Mehrizi
Ahmad Khajeh-Mehrizi
SNSaharnaz Nedjat
Saharnaz Nedjat
OAOmid Aminian
Omid Aminian

13 May 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HJHasan Jalaeikhoo
Hasan Jalaeikhoo
AKAhmad Khajeh-Mehrizi
Ahmad Khajeh-Mehrizi
Aplastic anemia (AA) is a rare disease in which hematopoietic stem cells are severely diminished resulting in hypocellular bone marrow and pancytopenia. Etiology of AA includes auto immunity, toxins, infection, ionizing radiation, drugs and rare genetic disorders, but in the majority of cases no cause can be identified. In the present study we assessed response rate, survival, relapse and clonal evolution in patients with AA treated with immunosuppressive therapy. Patients with AA who received immunosuppressive therapy between May 1998 and September 2013 were included in this study. Patients with non-severe AA (NSAA) were treated with cyclosporine (CsA) and danazol while patients with severe AA (SAA) as well as patients with NSAA who progressed to SAA after beginning of the treatment, were candidates for receiving antithymocyte globulin in addition to CsA and danazol. Among the 63 studied patients, 29 (46%) had NSAA and 34 (54%) had SAA. Three months after treatment, overall response was 58.6% in NSAA and 12.9% in patients with SAA. Survival of all patients at 5, 10 and 15 years were 73%, 55% and 49%, respectively. Survival rates were significantly higher in patients with NSAA compared to patients with SAA as well as in patients who responded at 6 months compared to non-responders. The relapse risk was 39.7% at 10 years. Relapse occurred in patients who discontinued the therapy more than those who continued taking CsA (p value<0.01). The risk of clonal evolution was 9.9% at 10 years and 22.8% at 15 years after treatment. This long-term retrospective study indicated that immunosuppressive therapy should be recommended to patients with AA. Also, our experience indicated that immunosuppressive therapy should not be discontinued after response to therapy in patients with both NSAA and SAA due to high risk of relapse. Low dose of CsA should be continued indefinitely.

1 January 2014
Verified
Journal Article
Closed access
KSKhosro Sadeghniiat-Haghighi
Khosro Sadeghniiat-Haghighi
HMHenry J Moller
Henry J Moller
MSMaryam Saraei
Maryam Saraei
OAOmid Aminian
Omid Aminian
AKAhmad Khajeh-Mehrizi
Ahmad Khajeh-Mehrizi

18 March 2025 in Journal of Medical Case Reports
Verified
Journal Article
Open access
AKAhmad Khajeh-Mehrizi
Ahmad Khajeh-Mehrizi
MKMehdi Karimi
Mehdi Karimi
MMMasoud Mortezazadeh
Masoud Mortezazadeh
HZHamidreza Zarei
Hamidreza Zarei
HHHoda Haghshenas
Hoda Haghshenas
FNFatemeh Nili
Fatemeh Nili
Renal-origin Ewing's sarcoma is an extremely rare malignancy often misdiagnosed owing to its nonspecific presentation and similarities to other renal tumors. Accurate diagnosis requires a combination of clinical evaluation and advanced diagnostic techniques. Limited case reports make understanding its clinical course and management challenging. This case report aims to raise awareness of renal-origin Ewing's sarcoma, highlight diagnostic challenges, and discuss effective multidisciplinary management strategies to improve patient outcomes. A 32-year-old Iranian female patient presented with a chief complaint of progressive dyspnea, anorexia, and night sweating in the last 2 weeks before her admission. Computed tomography scan showed a tumoral lesion in the left kidney with thrombosis extending into the left renal vein and inferior vena cava up to the right atrium. The patient underwent open cardiac surgery and a radical nephrectomy. During surgery, the mass protruded from the inferior vena cava into the right atrium; it was ultimately diagnosed as renal-origin Ewing's sarcoma, and EWSR1 rearrangement was confirmed on pathology. This case highlights the importance of a thorough diagnostic approach in patients presenting with a renal mass and the value of a multidisciplinary strategy, combining clinical presentation, imaging, histopathology, immunohistochemistry, and molecular studies to achieve an accurate diagnosis. It underscores the critical need for increased awareness and research into the rare entity of renal-origin Ewing's sarcoma, as clinical and pathological information on this condition is limited. Furthermore, this case emphasizes the necessity of timely diagnosis and tailored management to optimize treatment outcomes and improve survival rates in such rare and challenging presentations. not applicable.